Computing the Future of the Lab
Computational biology expert Keaun Amani shares his advice and insights on AI and machine learning tools for the clinical lab
Emerging Tests-dtet
Dissecting the Data Behind Healthcare AI
How do the underlying datasets affect artificial intelligence tools’ performance in the lab—and beyond?
Has Your AI Been Validated?
Many artificial intelligence-based medical devices have not undergone clinical validation—but what does this mean for the lab?
Removing Restrictions to Germline Testing
With the global cancer burden growing, is a universal germline genomic testing approach the key to more effectively combating the disease?
PGx Testing: First, Do No Harm
Recent advances in pharmacogenomic testing—and their role in ensuring safe, effective treatment selection for precision oncology
The Demand for Digital Pathology
When it comes to cancer, patients’ greatest fear is diagnostic delays—and they believe digital pathology and AI can reduce those delays
Syndromes Without a Name Bring Labs an Uphill Battle
In an era when genetic and genomic testing are theoretically affordable and accessible, why do so many patients remain undiagnosed?
Advances in Point of Care Tech Alter the Genetic Testing Landscape
How are advances in point-of-care testing altering the genetic testing landscape, and what does this mean for the clinical lab?
Molecular Mysteries in the Blood
The current landscape of molecular hematopathology—and what steps clinical labs can take to stay at the forefront of the discipline
The Latest Developments in Liquid Biopsy and ctDNA Testing
The latest developments in liquid biopsy and ctDNA testing and why they should be of interest to clinical laboratory professionals
Precision Psychiatry: How Far Off Are We?
Exploring the opportunities, challenges, and current research in lab-based testing for mental health disorders
Mind Reading: Lab Testing for Mental Health Conditions
What lab tests currently inform mental health care—and how might the testing landscape change as our understanding and technologies evolve?
Expert Q&A: Full Approval for Alzheimer’s Blood Tests Not Far Off
Andreas Jeromin, PhD, chief scientific officer at ALZPath, discusses the current landscape of blood-based AD tests and their future.
